Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 7Spondylitis, Ankylosing 2Psoriasis 2Colitis, Ulcerative 2Sarcoidosis 1Plaque Psoriasis 1Nephrotic Syndrome 1Nephrosis, Lipoid 1Mucopolysaccharidosis VI 1Mucopolysaccharidosis II 1Mucopolysaccharidosis I 1Mucopolysaccharidoses 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Inflammation 1Hidradenitis Suppurativa 1Glomerulosclerosis, Focal Segmental 1Dupuytren Contracture 1Crohn Disease 1Arthritis, Psoriatic 1Acne Vulgaris 1Abscess 1

Interventions

Certolizumab Pegol 3MEDI2070 2Infliximab 2secukinumab 1golimumab 1Vaccines 1Saline Solution 1Papillomavirus Vaccines 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Herpes Zoster Vaccine 1Calcium Dobesilate 1Calcitriol 1Bupivacaine 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Crohn Disease × Adalimumab × Clear all
NCT02499783 2019-01-04

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

AbbVie

Phase 3 Completed
205 enrolled 39 charts

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡